Back to Search Start Over

Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)

Authors :
Stephen Daw
P. Diez
William Townsend
Andre Lopes
Irfan Kayani
David C. Linch
Bal Sanghera
Peter Hoskin
Laura Clifton-Hadley
Sarah Leong
Graham P. Collins
Wai-Lup Wong
Kirit M. Ardeshna
Pip Patrick
Source :
British Journal of Haematology
Publication Year :
2019

Abstract

Summary This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30 years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease‐free survival (DFS) was 91%. We demonstrate that a risk‐stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy.

Details

ISSN :
13652141
Volume :
189
Issue :
1
Database :
OpenAIRE
Journal :
British journal of haematology
Accession number :
edsair.doi.dedup.....481f352379ad53f7ed5801f8f230eba1